This article presents a review of the major advances and future implications in precision oncology accomplished in 2022 and centers on three primary pillars: advances in (i) rational drug design, (ii) study design, and (iii) novel biomarkers.

©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.